Background
Hepatocellular carcinoma (HCC) has become one of the most frequently occurring cancers, and is considered to be highly lethal, accounting for approximately one-third of cancer-related deaths worldwide [
1,
2]. Despite advances in the understanding of the molecular mechanisms underlying HCC and improved treatments for HCC, the overall survival time is still limited [
3].
Current studies have shown that microRNAs (miRNAs) can act as activators or inhibitors of tumor metastasis by targeting multiple signaling pathways involved in metastasis [
4‐
6]. miR-22 is a 22-nt non-coding RNA and originally identified in HeLa cells as a tumor-suppressing miRNA. Subsequently, miR-22 was identified to be ubiquitously expressed in a variety of tissues [
7]. Recently, several targets of miR-22 were reported to mediate its tumorsuppressive effect, such as tumor-suppressive PTEN, Max genes, p21, Sp1, CD147 and oncogene c-myc expression, etc. [
7‐
11].
CD147 which is a 58-kDa transmembrane glycoprotein belonging to the immunoglobulin superfamily [
12,
13] is highly expressed in many tumors, including breast cancer, lymphoma, oral squamous cell carcinoma, glioma, melanoma, lung, bladder, liver and kidney carcinomas [
13‐
15]. It has been demonstrated that CD147 contributes significantly to tumor growth, metastasis and angiogenesis through stimulating the production of hyaluronan, multiple matrix metalloproteinases (MMPs) and vascular endothelial growth factor A (VEGF-A) [
16]. It has been reported that miR-22 inhibits cell migration and invasion through targeting CD147 in breast cancer [
11]. So we want to explore whether there exists this relationship of miR-22 and CD147 in the HCC progression.
In the current study, we validate the differential expression of miR-22 in HCC and investigated the function of miR-22 in migration and invasion of HCC cells. Furthermore, we identified CD147 as a target gene for miR-22 to regulate the invasion and metastasis of HCC cells in vitro. miR-22 might act as a tumor suppressor and serve as a potential therapeutic target in HCC. To the best of our knowledge, this is the first study to examine the regulation mechanism of miR-22 and CD147 in HCC migration and invasion.
Methods
HCC tissue specimens and immunohistochemical analysis
Thirty-four paired tissue specimens of HCC and adjacent non-tumor (ANT) tissues were obtained from Department of Hepatobiliary Surgery, Affiliated Traditional Chinese Medicine Hospital, Xinjiang Medical University. Informed consent was obtained from each patient. The thirty-four HCC tissues were divided into two groups: metastatic HCC tissues (patients with lung metastasis or portal vein cancer embolus, n = 20) and non-metastatic HCC tissues (n = 14). All of the tissues were obtained at the time of surgery and immediately stored in liquid nitrogen until use.
Immunohistochemistry was performed using Histostain-SP kits (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunopositivity was independently evaluated by two pathologists. Expression of protein was evaluated as described previously [
17,
18].
Cell lines and culture conditions
The following cell lines were used in this study: human normal liver cell QZG [
19], QSG-7701 [
20] and HL-7702 [
21]; human hepatocellular carcinoma cell lines: HepG2, BEL-7402, FHCC-98, SMMC-7721, HCC-9724, MHCC-97H (HCC cells with high metastatic potential) and MHCC-97L (HCC cells with low metastatic potential) [
22]. All cell lines were purchased from Shanghai Institute for Biological Sciences (Shanghai, China). All cell lines were routinely cultured in RPMI-1640 medium (Hyclone Laboratories, Logan, UT) supplemented with 10% fetal calf serum (Gibco BRL, Rockville, MD, USA) at 37 °C in a humidified atmosphere of 5% CO
2.
RNA extraction and real-time quantitative RT-PCR
Total RNA was isolated from tissues and cell lines by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Reverse transcription was performed using the Prime-Script RT reagent kit (TaKaRa, Otsu, Japan). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA and U6 small nuclear RNA were used as internal controls, respectively. All of the reactions were run in triplicate. Forward and reverse primers for miR-22, u6 snRNA, were 5′-AAGCTGCCAGTTGAAGAACTGTA-3′ and Universal Primer (Qiagen, Hilden, Germany), 5′-CTCGCTTCGGCAGCACA-3′ and 5′-AACGCTTCACGAATTTGCGT-3′, respectively. The primers for CD147 and GAPDH mRNA were 5′-TCGCGCTGCTGGGCACC-3′ and 5′-TGGCGCTGTCATTCAAGGA-3′, 5′-GGTCGGAGTCAACGGATTTG-3′ and 5′-ATGAGCCCCAGCCTTCTCCAT-3′, respectively. The relative expression levels were evaluated using the
ΔΔCt method [
15,
23].
Plasmid construction and luciferase activity assay
The miR-22 overexpression vector was constructed according to previous [
24] named as pcDNA3.1-miR-22. The full-length and mutant construct of CD147 3′-UTR were amplified [
11]. Pooled multiple siRNAs targeting CD147 [
25] were synthesized by Genepharma (Shanghai, China). All constructs were further confirmed by sequencing. Cell transfection and dual luciferase reporter assay were performed as described previously [
26].
Cell proliferation assay
Cells were plated in sixduplicate in 96-well plates (2 × 10
3 per well) in 100 μL complete medium and allowed to attach overnight. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (20 μL at 5 mg/mL; Sigma, St. Louis, MO) was added every 24 h and incubated for 4 h. The supernatant was discarded, the precipitate was dissolved in 200 μL dimethyl sulfoxide (DMSO), and plates were read with a microplate reader at 570 nm [
27].
Wound-healing assay
1 × 106 cells were seeded in six-well plates, cultured overnight, and transfected with miR-22 overexpression vector or NC, respectively. When the culture had reached nearly 90% confluency, the cell layer was scratched with a sterile plastic tip and then washed with culture medium twice and cultured again for up to 48 or 72 h with serum-reduced medium containing 1% FBS. At different time points, photographic images of the plates were acquired under a microscope and the data were summarized based on sextuple assays for each experiment.
In vitro invasion and migration assay
MilliCell (12 mm diameter with 8 µm pores) chambers (Millipore, Bedford, MA, USA) were pre-coated with Matrigel (BD, Bedford, MA, USA) on the upper side. A total of 1 × 105 serum-starved HCC cells were added to the upper compartment in medium supplemented with 0.1% serum, and the chambers were placed into 24-well plates with medium containing 10% serum. After 24 h at 37 °C, invaded cells on the lower membrane surface were fixed and stained with 0.1% crystal violet. Invasive activity was quantified by counting nine high-power fields (HPFs, 400×) per chamber. Mean values were obtained from at least three individual chambers for each experimental point per assay. The migration assay is the same with invasion assay excepting no matrigel was used and the permeating time for cells was 12 h.
In vivo proliferation assay
BALB/c nude mice at 4–6 weeks of age were provided by the Laboratory Animal Research Center of Xinjiang Medical University, and the animal study was reviewed and approved by the Xinjiang Medical University Animal Care and Use Committee. A total of 1 × 107 MHCC-97H cells stably expressing miR-22 were injected subcutaneously into nude mice. 60 days after injection, the mice were killed. Tumor volume was determined using direct measurement and calculated using the formula length × width2/2.
Western blot analysis
Cell samples were lysed with RIPA buffer (Beyotime, China). Equal amounts (10 μg) of total protein were loaded, and then subsequently immunoblotted with the primary antibodies, including anti-CD147 and tubulin monoclonal antibodies (Santa Cruz, CA, USA). Proteins were detected using the Amersham enhanced chemiluminescence system (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions.
Statistical analysis
All statistical analyses were performed using the SPSS 16.0 statistical software package (SPSS, Chicago, IL, USA). The significance of the data was determined using Student’s t test. All the statistical tests were two-sided, and a P < 0.05 was considered significant.
Discussion
Hepatocellular carcinoma is one of the most frequently occurring cancers with poor prognosis. Before the age of 60 years, HCC is the most commonly diagnosed cancer and the leading cause of cancer death in men [
28]. But novel diagnostic or prognostic biomarkers and therapeutic targets for HCC are urgently required. With the advance of high-resolution microarrays and massively parallel sequencing technology, miRNAs are suggested to play critical roles in the tumorigenesis and development of human HCC.
miRNAs have been demonstrated to have close relationship with HCC. miR-22, originally identified in HeLa cells, has been found to be overexpressed in prostate cancer, but down-regulated in breast cancer, cholangiocarcinoma, multiple myeloma, and hepatocellular carcinoma [
27]. miR-22 inhibits cell growth and induces cell-cycle arrest, apoptosis and senescence in breast cancer, colon cancer and lung cancer [
29]. miR-22 plays a tumor-suppressive role by downregulating oncogenic target genes in many kinds of cancer [
10,
24,
30,
31]. However, on the other side, miR-22 was recently suggested having an oncogenic role by targeting PTEN or TET family [
8,
32]. The reported paradoxical functions of miR-22 imply that miR-22 might act as a tissue/cell-specific or context-dependent tumor suppressor microRNA and the function diversely depending on its target genes and related regulatory networks. Perhaps, miR-22 may play more complex roles that exceed our perception in cancer, which needs us to explore it more deeply.
In this study, we demonstrated that miR-22 expression was decreased in HCC tissues and cell lines compared detected by real– time RT– PCR. Furthermore, the expression of miR-22 in metastatic HCC tissues was much lower than in no metastatic HCC tissues which indicated that the miR-22 expression was correlated with the HCC metastatic ability. Overexpression of miR-22 in MHCC-97H and SMMC-7721 cells significantly inhibited cellular proliferation, migration and invasion capability in vitro. In the HCC tumor models, miR-22 expression vector decreased the HCC tumors growth. Taken together, our results suggest that miR-22 worked as a tumor suppressor miRNA and contributed to inhibit HCC cells migration and invasion in vitro.
Previous work showed that CD147 was more strongly upregulated in HCC specimens than in the adjacent tissues and that this overexpression correlated with tumor metastasis and advanced histologic grades [
14,
33‐
35]. In the present study, we found an inverse correlation between miR-22 and CD147 expression in the HCC tissues. Our results are also shown that CD147 is negatively regulated by miR-22 at the posttranscriptional level, via a specific target site within the 3′UTR. miR-22 inhibits HCC cell migration and invasion through the CD147 pathway. Hence, our work indicates that miR-22 is an important suppressor in HCC invasion and metastasis, and CD147 seems to be a major downstream effector of miR-22 in its target network. Currently, the emergence of new technologies that use synthetic miRNA mimics or anti–miRNA oligonucleotides holds great promise for clinical miRNA therapy [
36]. Synthetic miR-22 mimic treatments for cancer will become a significant scientific and therapeutic challenge.
In conclusion, miR-22 down-expressed in HCC and the overexpression of miR-22 inhibited cell migration and invasion of HCC cells in vitro, and decrease HCC tumor growth in vivo. CD147 contains the binding site for miR-22 and is negatively regulated by miR-22. Down-regulation of CD147 mediated miR-22 function. This newly identified miR-22/CD147 link provides a new, potential therapeutic target to treat HCC.
Authors’ contributions
LJL and LPZ carried out the molecular genetic studies, animal studies and drafted the manuscript. CYD participated in the histologic study. PW and NNH participated in cell biology experiments. PA performed the statistical analysis. YL conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.